MONTE ROSA THERAPEUTICS ANNOUNCES COMPELLING CLINICAL ACTIVITY OF MRT-2359 IN COMBINATION WITH ENZALUTAMIDE IN HEAVILY PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH ANDROGEN RECEPTOR MUTATIONS

Reuters · 1d ago

Please log in to view news